TNX-801

Tonix schedules two TNX-801 vaccine sessions at Amsterdam congress

Image
Tonix schedules two TNX-801 vaccine sessions at Amsterdam congress

BERKELEY HEIGHTS -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) scheduled two sessions on its TNX-801 horsepox-based vaccine platform at World Vaccine Congress Europe in Amsterdam on Oct. 19-21, 2026. The company still lists the program as pre-IND, with a Phase 1 study not expected before 2027.

Tonix announced the sessions on Oct. 15, 2026, four days before the congress opened. Three of the four named speakers are Tonix employees. The fourth comes from the Kenya Medical Research Institute (KEMRI).